Testing effectiveness (Phase 2)Ended earlyNCT03420222
What this trial is testing
Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Intermittent Explosive Disorder
Who this might be right for
Intermittent Explosive Disorder
Otsuka Pharmaceutical Development & Commercialization, Inc. 10